Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration.

ABSTRACT: The enzyme poly-ADP-ribose-polymerase (PARP) has important roles for many forms of DNA repair and it also participates in transcription, chromatin remodeling and cell death signaling. Currently, some PARP inhibitors are approved for cancer therapy, by means of canceling DNA repair processes and cell division. Drug repurposing is a new and attractive aspect of therapy development that could offer low-cost and accelerated establishment of new treatment options. Excessive PARP activity is also involved in neurodegenerative diseases including the currently untreatable and blinding retinitis pigmentosa group of inherited retinal photoreceptor degenerations. Hence, repurposing of known PARP inhibitors for patients with non-oncological diseases might provide a facilitated route for a novel retini

SUBMITTER: Sahaboglu A 

PROVIDER: S-EPMC11104953 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature